More than 200 CF advocates from 47 states held nearly 400 meetings with members of Congress and their staff, and more than 850 advocates from across the country called their members of Congress as part of the CF Foundation's first March on the Hill online Day of Action.
- About the CF Foundation
- Public Policy
- Drug Pipeline
- CFTR Modulators
- Our Research Approach
- Genetic Therapies
- Health Care Reform
- Clinical Trials
- Get Involved
- North American CF Conference
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Care Centers
- Patient Assistance
- Infection Prevention and Control
- Patient Registry
- Coronavirus (COVID-19)
- Lung Transplantation
- In the Spotlight
- Diversity, Equity, and Inclusion
- Intro to CF
- Adult Care
- Clinician Resources
- Great Strides
- In Memoriam
- Researcher Resources
- Care Team
- CF-Related Complications
- CF Related Health Conditions
- Fertility and Reproductive Health
- (-) Our Advocacy Work
The Cystic Fibrosis Foundation responds to the Institute for Clinical and Economic Review's assessment of the comparative clinical effectiveness and value of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Today, the U.S. Senate released its version of the health care reform bill, titled the Better Care Reconciliation Act, and in response, the Cystic Fibrosis Foundation affirmed its opposition to the legislation.
The Institute for Clinical and Economic Review (ICER) developed an assessment of the comparative clinical effectiveness and value of cystic fibrosis therapies. The Foundation provided input to help inform this process.
Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.
Twelve patient/consumer groups urge senate to reject the bill.
Responding to the Trump administration's recent decision to freeze risk adjustment payments, the Cystic Fibrosis Foundation joined 13 other nonpartisan patient groups to voice disappointment in the latest administrative efforts to undermine adequate and affordable health care for people with pre-existing conditions.
Patient and provider groups urge the Senate to work together in a bipartisan fashion to ensure that Americans have access to affordable health care.